Related Experiment Video

Updated: Oct 11, 2025

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
09:28

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

8.8K

Treatment outcomes on neovascularization after CRAO treated with hyperbaric oxygen

Nicole Lifson1, George Salloum1, Philip Kurochkin1

  • 1Department of Ophthalmology, State University of New York Upstate Medical Center, Syracuse, New York, U.S.

Undersea & Hyperbaric Medicine : Journal of the Undersea and Hyperbaric Medical Society, Inc
|November 30, 2021
PubMed

Insights

Hyperbaric oxygen (HBO2) therapy may protect against neovascularization in central retinal artery occlusion (CRAO) patients. This treatment may also improve long-term visual acuity (VA) outcomes in CRAO cases.

Area of Science:

  • Ophthalmology
  • Vascular Medicine
  • Hyperbaric Medicine

Background:

  • Central retinal artery occlusion (CRAO) causes sudden vision loss from retinal artery obstruction.
  • Associated with atherosclerotic risk factors, CRAO leads to poor visual outcomes and neovascularization.
  • Current treatments for CRAO have limited efficacy in preventing neovascularization.

Purpose of the Study:

  • To evaluate the effectiveness of hyperbaric oxygen (HBO2) therapy in treating CRAO.
  • To assess the impact of HBO2 on visual acuity (VA) and neovascularization in CRAO patients.

Main Methods:

  • Retrospective analysis of CRAO patients undergoing HBO2 therapy.
  • Comparison of neovascularization rates and VA outcomes between patients with and without HBO2 treatment.

Main Results:

  • Neovascularization developed in 20% of patients treated with HBO2 versus 29.8% in the control group (p<.05).
  • HBO2 therapy demonstrated a statistically significant protective effect against neovascularization.
  • Potential for improved long-term visual acuity in CRAO patients receiving HBO2.

Conclusions:

  • Hyperbaric oxygen therapy shows promise as a treatment for central retinal artery occlusion.
  • HBO2 therapy may reduce the incidence of neovascularization and improve visual outcomes in CRAO.
  • Further research is warranted to confirm the long-term benefits of HBO2 for CRAO.

Keywords:
central retinal artery occlusionhyperbaric oxygen therapyneovascularizationvisual acuity

More Related Videos

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

14.6K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.6K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
376
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
746
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
242
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
274
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
885